INS and diabetes mellitus: The minor difference in the effect size observed in the CSII group may be attributed to patients familiarity with diabetes technology, the ability to administer a more precise insulin adjustment and utilising sensor‐augmented pump therapy with predictive low glucose suspend capabilities including other advanced hybrid closed loop features.19, 20